Novo Nordisk Logo - Search News

Novo Nordisk Skeptic Finally Upgrades Stock

Seeking Alpha · 20h

Novo Nordisk: Stock Plunges, But It May Be Time To Load Up

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.

Business Insider · 1d

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Seeking Alpha on MSN · 1d

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ diabetes drugs,

Business Insider · 2d

Novo Nordisk upgraded to Buy from Hold at Kepler Cheuvreux

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s

4don MSN

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

8don MSN

'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

4d

Novo Nordisk (0QIU) Receives a Buy from Goldman Sachs

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.

Investor's Business Daily on MSN4d

Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

4d

Novo’s Wegovy successor disappoints in second large trial

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results